Gilead Sciences, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; comparisons are with the three months ended March 31, 2023 unless stated otherwise. Amounts are in U.S. dollars.
Business context
Gilead is a global biopharmaceutical company focused on HIV, viral hepatitis, COVID-19 and cancer medicines. HIV products generated approximately 65% of Q1 product sales. The quarter included the CymaBay acquisition, adding investigational liver-disease candidate seladelpar.
Financial performance and liquidity
| Metric | Q1 2024 | Q1 2023 / prior balance |
|---|---|---|
| Total revenue | $6.686 billion | $6.352 billion; up 5% |
| Product sales | $6.647 billion | $6.306 billion; up 5% |
| Operating income (loss) | $(4.322) billion | $1.705 billion |
| Net income (loss) attributable to Gilead | $(4.170) billion | $1.010 billion |
| Diluted EPS | $(3.34) | $0.80 |
| Product gross margin | 76.6% | 77.8%; down 114 basis points |
| Operating cash flow | $2.219 billion | $1.744 billion |
| Cash and cash equivalents | $4.718 billion | $6.085 billion at December 31, 2023 |
| Cash, cash equivalents and marketable debt securities | $4.7 billion | $8.4 billion at December 31, 2023 |
| Total debt and related obligations, carrying value | $25.193 billion | $24.987 billion at December 31, 2023 |
Q1 investing cash outflow was $2.207 billion, including the CymaBay acquisition; financing cash outflow was $1.361 billion, including $990 million of dividends and $400 million of share repurchases. Gilead sold all available-for-sale debt securities during the quarter to help fund the acquisition. Its $2.5 billion revolving credit facility had no borrowings outstanding at quarter-end.
Revenue trends and changes
- HIV: Sales rose 4% to $4.342 billion, primarily on higher demand. Biktarvy increased 10% to $2.946 billion, while Genvoya declined 20% to $403 million.
- Liver disease: Sales rose 9% to $737 million, attributed to inventory and purchasing timing as well as demand across HBV, HCV and HDV products.
- Veklury: Sales declined 3% to $555 million, primarily reflecting fewer COVID-19-related hospitalizations.
- Oncology: Sales rose 18% to $789 million. Trodelvy increased 39% to $309 million; cell therapy sales increased 7% to $480 million.
- Costs: Cost of goods sold rose 11%, and product gross margin fell, reflecting product mix and higher Trodelvy intangible-asset amortization. R&D rose 5% to $1.520 billion; SG&A rose 4% to $1.375 billion.
Unusual items, outlook and management commentary
- The $4.131 billion acquired in-process R&D expense was driven chiefly by a $3.9 billion charge for CymaBay’s seladelpar asset, which Gilead accounted for as an asset acquisition. The charge was non-deductible for tax purposes.
- Gilead recorded a $2.430 billion impairment charge on acquired Trodelvy IPR&D for metastatic NSCLC after the Phase 3 EVOKE-01 study failed to meet its overall-survival primary endpoint. The remaining estimated fair value was $3.5 billion; further impairment could result if key assumptions or development prospects worsen.
- Arcus collaboration-related items included a $100 million option-continuation fee charged to acquired IPR&D expense and an $87 million premium charged to other expense. The $100 million payment was expected by Q3 2024.
- The effective tax rate was 7.0%, versus 24.3% a year earlier, mainly reflecting the non-deductible CymaBay IPR&D charge, partly offset by other tax items. The company also reported a roughly $400 million reduction in unrecognized tax benefits following conclusion of a tax audit.
- Seladelpar’s application was accepted for FDA priority review, with an August 14, 2024 target action date. No new numerical full-year guidance is provided in this 10-Q text.
- In February 2024, Gilead said it would not pursue further magrolimab development in hematologic cancers. It also discontinued further enrollment in the Phase 3 ARC-10 study of domvanalimab plus zimberelimab as part of strategic prioritization.
- In April 2024, after quarter-end, Gilead repaid $1.75 billion of notes at maturity and made a scheduled $1.2 billion federal transition-tax payment.
- Key risks include reliance on HIV sales, competition and generic entry, pricing and reimbursement pressure, clinical-trial and regulatory uncertainty, manufacturing and supply constraints, foreign-exchange exposure, and litigation. The filing cites product-liability cases involving approximately 25,000 active plaintiffs and ongoing antitrust and generic-patent disputes. No material accruals were recorded for the described legal matters at March 31, 2024.
- Management concluded disclosure controls were effective as of March 31, 2024. ERP implementation is continuing in phases and may affect operations or internal controls during the transition.
Important facts for investors to verify
- Whether seladelpar receives FDA approval by its August 14, 2024 target date, and its commercial prospects if approved.
- Whether Trodelvy’s NSCLC development assumptions support the $3.5 billion remaining IPR&D valuation, or lead to further impairment.
- How the post-acquisition cash position, April debt repayment and tax payment affect liquidity and future capital allocation.
- Whether HIV growth, particularly Biktarvy performance, can offset product transitions, competition and pricing or reimbursement pressures.
- Developments in the approximately 25,000 product-liability cases, antitrust litigation and patent challenges to Biktarvy, Symtuza and Genvoya.
- Actual performance against any later-issued full-year guidance; this filing does not provide a new numerical forecast.